Lechaim Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 28.13%
- Profit Growth -2263.08%
- Ebitda -8.31%
- Net Worth -19.36%
- Total Assets 2.85%
About Lechaim Pharma
Lechaim Pharma Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 October 2012 and has a history of 12 years and three months. Its registered office is in Thrissur, Kerala, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Arunkumar Padipuraveetil, Chakkalayil Sam, Shine Chazhur, and One other member serve as directors at the Company.
Company Details
-
Location
Thrissur, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397KL2012PTC032420
-
Company No.
032420
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Oct 2012
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Lechaim Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Byju Sethumadavan
|
Director | 17-Oct-2012 | Current |
|
Arunkumar Padipuraveetil
|
Director | 17-Oct-2012 | Current |
|
Chakkalayil Sam
|
Director | 17-Oct-2012 | Current |
|
Shine Chazhur
|
Director | 17-Oct-2012 | Current |
Financial Performance of Lechaim Pharma.
Lechaim Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 28.13% increase. The company also saw a substantial fall in profitability, with a 2263.08% decrease in profit. The company's net worth observed a substantial decline by a decrease of 19.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lechaim Pharma?
Unlock access to Lechaim Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Indvocare Private LimitedShine Chazhur is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lechaim Pharma?
Unlock and access historical data on people associated with Lechaim Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lechaim Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lechaim Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.